相关实验视频

Updated: Jan 12, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

对于B细胞恶性瘤的CAR T细胞疗法后的二次恶性瘤:回顾性分析

Joanne Britto1,2,3, Audrey Y H Dong1, Gregory Pond2,4

  • 1Faculty of Health Sciences McMaster University Hamilton Ontario Canada.

EJHaem
|October 30, 2025
PubMed
概括

化学抗原受体T细胞 (CART) 治疗后可能发生二次恶性瘤. 这项研究发现,在接受CART治疗的患者中,骨髓性恶性瘤,如AML和MDS的发病率为8.0%.

关键词:
汽车车上的车辆.骨髓性恶性瘤是一种恶性瘤.二次的初级恶性瘤.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K